BioLife Solutions (BLFS) Earns Daily News Sentiment Score of 0.37

News articles about BioLife Solutions (NASDAQ:BLFS) have trended positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioLife Solutions earned a media sentiment score of 0.37 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 45.7631480038121 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Separately, Maxim Group set a $8.00 target price on BioLife Solutions and gave the company a “buy” rating in a research report on Thursday, January 4th.

Shares of BioLife Solutions (NASDAQ BLFS) traded down $0.10 during trading hours on Thursday, reaching $4.80. The company had a trading volume of 50,527 shares, compared to its average volume of 65,016. BioLife Solutions has a 12 month low of $1.77 and a 12 month high of $7.53. The firm has a market cap of $65.43, a price-to-earnings ratio of -11.43 and a beta of 0.32.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, November 9th. The medical equipment provider reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. BioLife Solutions had a negative return on equity of 49.92% and a negative net margin of 52.10%. The company had revenue of $2.96 million for the quarter, compared to analyst estimates of $2.60 million. research analysts expect that BioLife Solutions will post -0.21 EPS for the current year.

In related news, CEO Michael Rice sold 12,540 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $5.57, for a total transaction of $69,847.80. Following the transaction, the chief executive officer now directly owns 152,057 shares of the company’s stock, valued at approximately $846,957.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 36.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://sportsperspectives.com/2018/02/08/biolife-solutions-blfs-earns-daily-news-sentiment-score-of-0-37.html.

About BioLife Solutions

BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply